Published in Drug Week, January 28th, 2005
The company's NDA for Enjuvia (synthetic conjugated estrogens, B) 0.625 mg and 1.25 mg tablets received FDA approval in May 2004.
The company's Enjuvia product line includes the lowest dose, plant- derived, synthetic conjugated estrogen product approved for the treatment of vasomotor symptoms. Enjuvia tablets contain a blend of 10 synthetic estrogenic substances, including the component...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.